Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an announcement.
Botanix Pharmaceuticals has promoted Paul Seaback to Chief Operating Officer, expanding his remit from Chief Technical Officer to overseeing day-to-day operations and strategic initiatives across the business. With more than 30 years of experience in innovator, generic and specialty pharmaceuticals, his background includes senior roles at Dermavant, Roche, Gilead and other major drug makers, where he helped scale operations and commercialise products such as Sovaldi, Harvoni and Truvada.
The company said the appointment is aimed at optimising operational performance, enhancing cross-functional collaboration and building scalable processes to support Botanix’s next phase of growth. Management framed the move as a key step in strengthening execution as Botanix expands commercial capabilities around Sofdra and seeks to deliver greater value to customers and shareholders.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company based in Philadelphia and Phoenix that focuses on innovative treatments for skin conditions. The company has received U.S. FDA approval for Sofdra, the first and only new chemical entity approved to treat primary axillary hyperhidrosis, offering a novel option to patients with limited prior therapies.
Average Trading Volume: 22,786,439
Technical Sentiment Signal: Sell
Current Market Cap: A$73.45M
Learn more about BOT stock on TipRanks’ Stock Analysis page.